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Abstract
Background:  Former meta-analyses have shown a survival benefit for the addition of chemotherapy (CHX) to
radiotherapy (RT) and to some extent also for the use of hyperfractionated radiation therapy (HFRT) and accelerated
radiation therapy (AFRT) in locally advanced squamous cell carcinoma (SCC) of the head and neck. However, the
publication of new studies and the fact that many older studies that were included in these former meta-analyses used
obsolete radiation doses, CHX schedules or study designs prompted us to carry out a new analysis using strict inclusion
criteria.
Methods: Randomised trials testing curatively intended RT (≥60 Gy in >4 weeks/>50 Gy in <4 weeks) on SCC of the
oral cavity, oropharynx, hypopharynx, and larynx published as full paper or in abstract form between 1975 and 2003 were
eligible. Trials comparing RT alone with concurrent or alternating chemoradiation (5-fluorouracil (5-FU), cisplatin,
carboplatin, mitomycin C) were analyzed according to the employed radiation schedule and the used CHX regimen.
Studies comparing conventionally fractionated radiotherapy (CFRT) with either HFRT or AFRT without CHX were
separately examined. End point of the meta-analysis was overall survival.
Results: Thirty-two trials with a total of 10 225 patients were included into the meta-analysis. An overall survival benefit
of 12.0 months was observed for the addition of simultaneous CHX to either CFRT or HFRT/AFRT (p < 0.001). Separate
analyses by cytostatic drug indicate a prolongation of survival of 24.0 months, 16.8 months, 6.7 months, and 4.0 months,
respectively, for the simultaneous administration of 5-FU, cisplatin-based, carboplatin-based, and mitomycin C-based
CHX to RT (each p < 0.01). Whereas no significant gain in overall survival was observed for AFRT in comparison to
CFRT, a substantial prolongation of median survival (14.2 months, p < 0.001) was seen for HFRT compared to CFRT
(both without CHX).
Conclusion:  RT combined with simultaneous 5-FU, cisplatin, carboplatin, and mitomycin C as single drug or
combinations of 5-FU with one of the other drugs results in a large survival advantage irrespective the employed radiation
schedule. If radiation therapy is used as single modality, hyperfractionation leads to a significant improvement of overall
survival. Accelerated radiation therapy alone, especially when given as split course radiation schedule or extremely
accelerated treatments with decreased total dose, does not increase overall survival.
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Background
The disappointing results of conventionally fractionated
radiotherapy in locally advanced squamous cell cancer of
the head caused investigators to test new treatment strate-
gies. Based on retrospective clinical data and radiobiologi-
cal considerations hyperfractionated and accelerated
radiation regimens as well as chemoradiation regimens
have been investigated in a large number of clinical trials.
Hyperfractionation and acceleration of radiotherapy has
been identified as potentially advantageous compared to
conventionally fractionated radiotherapy in comprehen-
sive reviews [1] and a former meta-analysis [2]. However,
the existence of a real benefit has been challenged [3,4]
and neither hyperfractionation nor acceleration has been
widely accepted as standard of care. The availability of the
results of a number of new studies prompted us to carry
out a new meta-analysis.
The addition of chemotherapy to radiotherapy was ana-
lysed in the MACH-NC meta-analysis and showed a small
but significant survival advantage in favour of chemother-
apy (4% at 5 years), which was higher (8% at 5 years, haz-
ard ratio (HR) 0.81) in case of simultaneous
radiochemotherapy compared to sequential or adjuvant
chemotherapy [5]. An update of this meta-analysis [6]
including 87 trials and more than 16 000 patients con-
firmed the results of the earlier analysis. Although, some
information in the MACH-NC meta-analysis is provided
about relevant subgroups of studies, we felt that a more
detailed look at the radiation dose and fractionation
schedules and the employed chemotherapy regimens
used in the chemoradiation trials is of interest. Further-
more, we think that neither studies using drugs that are no
longer in clinical use in combination with concurrent
radiotherapy in head and neck cancer, because of docu-
mented severely enhanced acute mucosal toxicity (bleo-
mycin and methotrexate) nor studies using subcurative
radiation schedules in the radiotherapy alone arm should
be included into a meta-analysis, if one wants to get clin-
ically meaningful conclusions. Therefore, our study group
performed a meta-analysis based on randomised trials ful-
filling strictly defined entry criteria that tested concurrent
or alternating chemoradiation versus radiation therapy
alone.
Methods
Eligibility criteria for clinical trials
Three groups of randomised trials on patients with squa-
mous-cell carcinoma of the head and neck (oral cavity,
oropharynx, hypopharynx, and larynx) without distant
disease using radical radiotherapy in the control arms of
the studies were eligible: 1. Studies comparing radiother-
apy to radiotherapy in combination with chemotherapy.
2. Studies comparing conventionally fractionated radio-
therapy (CFRT) to accelerated fractionated radiotherapy
(AFRT). 3. Studies comparing conventionally fractionated
radiotherapy to hyperfractionated radiotherapy (HFRT).
No surgery other than neck dissection after primary treat-
ment was allowed. Trials on nasopharyngeal carcinomas
were excluded. Radical radiotherapy in the control arms
of the studies was defined as the administration of at least
60 Gy total dose, if the overall treatment time was longer
than 4 weeks, and the administration of at least 50 Gy, if
the overall treatment time was below or equal to 4 weeks.
Studies using lower total doses were excluded, because
such treatment was considered palliative radiotherapy.
More details on the eligibility criteria in the specific sub-
groups are given in the following paragraphs:
1. Comparison of radiotherapy vs. radio-chemotherapy
Only trials comparing radiotherapy alone with radio-
chemotherapy using simultaneous or alternating cispla-
tin, carboplatin, mitomycin C, and 5-fluorouracil (5-FU)
as single drug or combinations of 5-FU with a platinum-
derivate were eligible. Studies using bleomycin or meth-
otrexate containing chemotherapy regimens were
excluded, because these drugs have been shown to dra-
matically enhance radiation induced mucositis and skin
reaction [7,8] and are therefore no longer in clinical use in
combination with radiotherapy in most countries. Radio-
chemotherapy trials were divided into three groups:
Group 1a included studies comparing CFRT alone in the
control arms with CFRT in combination with simultane-
ous chemotherapy in the experimental arms of the stud-
ies. The difference in overall treatment time had to be
≤1%, and the difference in total radiation dose ≤1%
between the control and the experimental arms of the
studies, respectively.
Group 1b included studies comparing HFRT or AFRT
alone in the control arms with HFRT or AFRT in combina-
tion with simultaneous chemotherapy in the experimen-
tal arms of the studies. To be considered as accelerated
radiation more than 10 Gy total dose per week had to be
administered on average during the radiation series. HFRT
required the application of at least 2 daily fractions for at
least one third of the radiation series. The difference in
overall treatment time had to be ≤11%, and the difference
in total radiation dose ≤11% between the control and the
experimental arms of the studies, respectively.
Group 1c included studies with a substantial imbalance of
the radiation regimen used in the control and the experi-
mental arm of the studies. CFRT, HFRT or AFRT alone in
the control arms were compared with similar fractionated
radiation regimens, but large differences in overall treat-
ment time and/or total radiation dose in combination
with alternating or simultaneous chemotherapy in the
experimental arms of the studies. Either the difference inBMC Cancer 2006, 6:28 http://www.biomedcentral.com/1471-2407/6/28
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overall treatment time had to be >11%, or the difference
in total radiation dose had to be >11% between the con-
trol and the experimental arms of the studies.
2. Comparison of conventionally fractionated radiotherapy vs. 
accelerated radiotherapy
Group 2 included studies comparing CFRT alone in the
control arms with AFRT in the experimental arms of the
studies. To be considered as accelerated radiation the
overall treatment time had to be 10–50% shorter in the
experimental arm of the study, if the total dose was
decreased by no more than 5%, and had to be more than
50% shorter in the experimental arm of the study, if the
total dose was decreased by more than 5%.
3. Comparison of conventionally fractionated radiotherapy versus 
hyperfractionated radiotherapy
Group 3 included studies comparing CFRT alone in the
control arms with HFRT in the experimental arms of the
studies. Hyperfractionation was defined as twice daily
radiation treatments with <1.25 Gy per fraction. Further-
more, the overall treatment time was not allowed to vary
by more than 10% between treatment arms and the total
radiation dose had to be increased by at least 5% in the
hyperfractionated arms of the studies. Studies using
hyperfractionated radiotherapy without dose escalation
or even with lower total doses in the hyperfractionated
arm of the study were excluded, because these studies did
not exploit the inherent radiobiological advantage of
hyperfractionation that allows for dose escalation.
Literature search strategy
The meta-analysis aimed to include trials published as full
paper or at least in published abstract form between Janu-
ary 1975 and December 2003 with overall survival data
(for at least two time points or survival curves). Electronic
databases (Medline, PubMed, and CancerLit) were
searched to identify potentially eligible trials. In addition,
reference lists of published reports, review articles, and
relevant books were searched.
Exclusion of specific studies
A study from Haffty et al. [9] was excluded, because results
of surgically and non-surgically treated patients were not
reported separately. A trial published by Poulsen et al.
[10] on accelerated radiotherapy could not be included
into the meta-analysis, because only disease specific sur-
vival, but not overall survival data has been reported.
Only trials with at least 60 randomised patients were con-
sidered [11]. A list of further trials not fulfilling our entry
Difference of survival comparing conventionally fractionated radiotherapy with conventionally fractionated radiotherapy plus  simultaneous chemotherapy using cisplatin, carboplatin, mitomycin C, and 5-fluorouracil as single drug or combinations of 5-FU  with a platin-derivate (Group 1a) Figure 1
Difference of survival comparing conventionally fractionated radiotherapy with conventionally fractionated radiotherapy plus 
simultaneous chemotherapy using cisplatin, carboplatin, mitomycin C, and 5-fluorouracil as single drug or combinations of 5-FU 
with a platin-derivate (Group 1a). OS = Overall survival; * = 95% confidence limits of 2 year overall survival; delta months = dif-
ferences of median overall survival; LCL = lower confidence limit of median survival; UCL = upper confidence limit of median 
survival; N = number of patients.BMC Cancer 2006, 6:28 http://www.biomedcentral.com/1471-2407/6/28
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criteria with the reasons for exclusion is given in the
appendix (see additional file #1).
Statistical methods
Overall survival was the end point of the meta-analysis.
The meta-analysis was based on overall survival probabil-
ities at 1, 2, 3 and, if available, at 5 years that were
extracted from published papers, original patient's data (1
study [12]), or estimated from published Kaplan-Meier
curves. Based on the sample sizes the absolute numbers of
patients were calculated, who were expected to have died
during the first year, the second year, the third year, during
the time between the third and the fifth year, and who sur-
vived the last year of observation. Using maximum likeli-
hood, a lognormal distribution was fitted to these
numbers. The statistical model assumes that the control
group and the treated group have the same standard devi-
ation of the logarithms. For each study, a parameter for
the mean was calculated for the control group. The com-
mon difference to the control group was estimated for all
studies which are concerned with the same treatment.
Using maximum likelihood methods, a 95% confidence
interval for the gain in the median survival was calculated.
Only the number of patients who were expected to survive
the last year of observation (year 3 or 5) entered the calcu-
lations as censored variables. The authors are aware of the
fact that this approach does not take into account censor-
ing before the last year of observation, but the paucity of
information provided in the publications left no other
choice. The present method does not affect the estimates
of median survival. Only the width of the confidence
intervals is underestimated. The goodness of fit of the log-
normal model with the observations was assessed with
the chi-square test (see additional file #2). The reason to
choose the gain in median overall survival as end point of
the meta-analysis rather than hazard ratios is a conse-
quence of the observation that the hazard ratio decreased
significantly over time in some of the included studies.
This time dependent changes of the hazard ratios in some
studies did not allow for a reliable estimate of the overall
hazard ratio for all studies, whereas the gain in overall sur-
vival could be reliably estimated. Using the lognormal
survival distribution it is possible to transform the gain in
median survival into a gain of the survival probability at
two years after the beginning of therapy together with the
95% confidence intervals. For each comparison a chi-
square test for heterogeneity was performed.
Results
Thirty-two trials with a total of 10 225 patients were iden-
tified and included into the meta-analysis. Group 1a, 1b,
1c, 2 and 3 consisted of 10, 6, 3, 9, and 4 trials including
2197, 1301, 502, 4702, and 1523 patients, respectively.
The exact distribution of T- and N-stages was not available
for all but for most trials. TMN stages were taken from the
publications without reclassification according to a more
recent TMN-classification. Looking at the median values
of the available data on stage distribution, 26% (range 0%
to 83%) had stage III and 69% (range 0–96%) had stage
IV M0 disease, 14% (range 0% to 47%) suffered from N3-
lymph node involvement, indicating that the vast major-
ity of patients treated in the trials of interest had locally
Difference of survival comparing hyperfractionated or accelerated radiotherapy with hyperfractionated or accelerated radio- therapy plus simultaneous chemotherapy using cisplatin, carboplatin, mitomycin C, and 5-FU as single drug or combinations of  5-FU with one of the other drugs (Group 1b) Figure 2
Difference of survival comparing hyperfractionated or accelerated radiotherapy with hyperfractionated or accelerated radio-
therapy plus simultaneous chemotherapy using cisplatin, carboplatin, mitomycin C, and 5-FU as single drug or combinations of 
5-FU with one of the other drugs (Group 1b). OS = Overall survival; * = 95% confidence limits of 2 year overall survival; delta 
months = differences of median overall survival; LCL = lower confidence limit of median survival; UCL = upper confidence limit 
of median survival; N = number of patients.BMC Cancer 2006, 6:28 http://www.biomedcentral.com/1471-2407/6/28
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advanced head and neck cancer. As expected, predomi-
nantly male patients (median percentage 85%, range 74%
to 94%) had been included into the studies.
The analysis on CFRT in combination with simultaneous
chemotherapy (CF-RT, group 1a) resulted in an overall
survival benefit of 12.0 months (95% confidence limits
(CI) 7.7 to 16.9 months) compared with CF-RT alone (p
< 0.0001, figure 1, table 1). HFRT and/or AFRT in combi-
nation with simultaneous chemotherapy (HFRT/AFRT,
group 1b) resulted in a similar overall survival benefit of
12.0 months (95% CI: 6.7 to 18.8 months) compared
with HFRT/AFRT alone (p < 0.0001, figure 2, table 2). A
smaller overall survival advantage of 7.9 months (95% CI:
0.7 to 19.1 months) was seen, if imbalanced radiation reg-
imens were used in combination with simultaneous or
alternating chemotherapy (Imbalanced-RT, group 1c)
compared with radiotherapy alone (p < 0.001, figure 3,
table 3). Differences in the gain of overall survival
between group 1a, 1b, and 1c did not reach statistical sig-
nificance.
The effect of different chemotherapeutic agents given
simultaneously with radiotherapy, either conventionally
fractionated or hyperfractionated/accelerated was ana-
lysed separately using the same studies: 5-fluorouracil as
sole chemotherapy revealed an increase in overall survival
time of 24.0 months (95% CI: 18.1 to 30.8 months, trial#
1, 2, 3), cisplatin based chemotherapy of 16.2 months
(95% CI: 11.8 to 21.4 months, trial #4,5,8,12,13,14,15),
carboplatin of 6.7 months (95% CI: 3.7 to 10.1 months,
trial #6,9,10,16), and mitomycin of C 4.0 months (95%
CI 1.6 to 6.9 months, trial #7,17,18), respectively (figure
4).
No survival benefit was observed in 8 out of 9 studies that
tested AFRT versus CFRT (group 2). The large survival
advantage reported from a smaller polish trial [13] that
Table 1: Conventionally fractionated radiotherapy with or without simultaneous chemotherapy using cisplatin, carboplatin, mitomycin 
C, and 5-FU as single drug or combinations of 5-FU with platinum-derivate (group 1a)
control arm experimental arm












Sanchiz [18] 1 60 42.0 60 42.0 3750 30
Lo [24] 2 66 56.0 66 56.0 5500 41 38
Browman [25] 3 66 45.5 66 45.5 7200 55 14
J e r i m i c  [ 2 6 ] 47 05 0 . 87 05 0 . 8 2 2 2 8 6 1 6
Adelstein [27] 5 70 49.0 70 49.0 300 94 28
J e r e m i c  [ 2 6 ] 67 05 0 . 87 05 0 . 8 9 2 5 8 6 1 9
G r a u  [ 2 8 ] 76 64 7 . 06 64 7 . 0 3 05 3 4
Adelstein [29] 8 70 49.0 70 49.0 160 8000 72 31
Olmi [30] 9 68 47.3 68 47.25 900 12000 75 7
Denis, Calais [31,32] 10 70 49.0 70 49.0 840 7200 68 13
DDP = cisplatin cumulative dose [mg/m2]; Carbo = carboplatin cumulative dose [mg/m2]; 5-FU = 5-fluorouracil cumulative dose [mg/m2]; FA = 
folinic acid; MMC = mitomycin C cumulative dose [mg/m2]
Table 2: Optimised radiotherapy (hyperfractionation or acceleration) with or without simultaneous chemotherapy using cisplatin, 
carboplatin, mitomycin C, and 5-FU as single drug or combinations of 5-FU with one of the other drugs (Group 1b, no significant 
difference in overall treatment time between treatment arms)
control arm experimental arm












Jeremic [33] 11 77 49 77 49 210 82 18
Brizel [34] 12 75 42 70 40 120 6000 13
Wendt [35] 13 70.2 56 70.2 56 180 4200 1350 14
Staar [36] 14 69.4 38 69.4 38 700 6000 96 10
Dobrowsky [37] 15 55.3 17 55.3 17 20 82 13
Budach [12] 16 77.6 42 70.4 42 3000 20 94.5 14
DDP = cisplatin cumulative dose [mg/m2]; Carbo = carboplatin cumulative dose [mg/m2]; 5-FU = 5-fluorouracil cumulative dose [mg/m2]; FA = 
folinic acid; MMC = mitomycin C cumulative dose [mg/m2]BMC Cancer 2006, 6:28 http://www.biomedcentral.com/1471-2407/6/28
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compared 5 days a week to 7 days a week radiotherapy is
completely out of the range of the experience of all other
studies. Nevertheless, including all studies no significant
overall survival benefit (1.1 months, 95% CI -1.4 to 4.7
months) was observed comparing AFRT (group 2) with
CFRT (figure 5, table 4).
Overall survival after HFRT (group 3) was consistently
better than overall survival after CFRT in all four pub-
lished trials. A survival benefit of 14.2 months (95% CI:
10.2 to 18.5 months) was observed in favour of HFRT (p
< 0.001, figure 6, table 4).
The survival advantage of HFRT (figure 5) compared to
CFRT was significantly larger than the modest (non signif-
icant) benefit of AFRT (figure 6) compared to CFRT radio-
therapy (likelihood ratio test χ2 = 36.2, p-value < 10-4)
The chi-square tests for heterogeneity of each comparison




We identified 20 trials with a total of 4000 patients fulfill-
ing the strict entry criteria for the comparison of radiation
therapy alone with simultaneous or alternating chemora-
diation. A large survival benefit of 12.0 months was
observed in favour of simultaneous chemoradiation irre-
spective of whether conventionally fractionated (Figure
1), hyperfractionated or accelerated radiation schedules
(Figure 2) were used. A smaller, but statistically still signif-
icant survival advantage of 7.9 months was seen in the
three studies that used prolonged overall treatment times
(≥1 week) in the chemoradiation arms due to alternating
Difference of survival comparing altered fractionated radiotherapy with altered fractionated radiotherapy plus chemotherapy  using combinations of 5-FU with cisplatin or mitomycin C (Group 1c) Figure 3
Difference of survival comparing altered fractionated radiotherapy with altered fractionated radiotherapy plus chemotherapy 
using combinations of 5-FU with cisplatin or mitomycin C (Group 1c). This group of trials showed a relevant difference/prolon-
gation in overall treatment time (delta 7 – 28 days) between standard and experimental treatment arm, caused by split course 
treatment or rapidly alternating radio-chemotherapy. OS = Overall survival; * = 95% confidence limits of 2 year overall survival; 
delta months = differences of median overall survival; LCL = lower confidence limit of median survival; UCL = upper confi-
dence limit of median survival; N = number of patients.
Table 3: Altered fractionated radiotherapy with or without chemotherapy using combinations of 5-FU with cisplatin or mitomycin C; 
only trials with a relevant prolongation in overall treatment time, caused by planned split course treatment or rapidly alternating 
radiochemotherapy (Imbalanced-RT, group 1c)
control arm experimental arm












Keane [38] CF split 17 50 28 50 56 8000 20 47 17
Corvo [39] alter. CF 18 75 42 60 56 400 4000 82 12
Merlano [40] alter. CF 19 70 49 60 56 400 4000 75 31
DDP = cisplatin cumulative dose [mg/m2]; Carbo = carboplatin cumulative dose [mg/m2]; 5-FU = 5-fluorouracil cumulative dose [mg/m2]; FA = 
folinic acid; MMC = mitomycin C cumulative dose [mg/m2]BMC Cancer 2006, 6:28 http://www.biomedcentral.com/1471-2407/6/28
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chemoradiation or planned treatment breaks (Figure 3).
Looking at the potential survival gain by cytostatic drugs,
5-FU as single drug and cisplatin as single drug or in com-
bination with 5-FU exhibited the largest benefit. Carbopl-
atin +/- 5-FU and mitomycin C +/- 5-FU were less
effective, although the survival gain was statistically still
significant (Figure 4). The survival benefit of 12.0 months
seen for simultaneous chemoradiation schedules in stud-
ies that did not significantly prolong overall treatment
time in the chemoradiation arm corresponds to an abso-
lute survival gain of 13%–15% at 2 years. This benefit is
almost twice as large as the benefit that has been reported
form the update of the MACH-NC meta-analysis for
simultaneous chemoradiation [5,6]. The MACH-NC
Difference of median survival with different drugs used for concomitant radiochemotherapy compared to radiotherapy alone,  χ2 => p-value = 0.04 Figure 4
Difference of median survival with different drugs used for concomitant radiochemotherapy compared to radiotherapy alone, 
χ2 = > p-value = 0.04. 5-fluorouracil: studies with simultaneus 5-fluorouracil chemotherapy [18,24,25,38]. Cisplatin: studies 
with simultaneus cisplatin based chemotherapy [26,27,29,33,34,35,39,40]. Carboplatin: studies with simultaneus carboplatin 
based chemotherapy [26,30,31,32,36]. Mitomycin C: studies with mitomycin C based chemotherapy [12,30,37]. LCL = 95% 
lower confidence limit, UCL = 95% upper confidence limit; N = number of patients.
Comparison of accelerated radiotherapy with conventionally fractionated radiotherapy (Group 2) Figure 5
Comparison of accelerated radiotherapy with conventionally fractionated radiotherapy (Group 2). OS = Overall survival; * = 
95% confidence limits of 2 year overall survival; delta months = differences of median overall survival; LCL = lower confidence 
limit of median survival; UCL = upper confidence limit of median survival; N = number of patients.BMC Cancer 2006, 6:28 http://www.biomedcentral.com/1471-2407/6/28
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meta-analysis included 50 studies on simultaneous chem-
oradiation regardless of the employed chemotherapy reg-
imen and radiation dose. The inclusion of studies using
bleomycin or methotrexate containing chemoradiation
regimens into the MACH-NC meta-analysis is the main
reason for the considerably smaller survival advantage.
Methotrexate and bleomycin have both been shown to
considerably enhance acute mucosal toxicity that will
most likely result via consequential late effects in an
increased late toxicity [7,14,15]. These observations and
the lack of an obvious survival benefit prompted all large
study groups to abandon the use of bleomycin and meth-
otrexate in combination with simultaneous radiation
therapy in head and neck cancer. Therefore, at least to our
minds, it does not make sense to include theses studies
into a meta-analysis, if one wants to estimate the real ben-
efit of modern chemoradiation schedules in head and
neck cancer patients. Similar arguments apply for studies
that used, according to our current knowledge, subcura-
tive total radiation doses. These studies were included into
the MACH-NC meta-analysis, but excluded from the
meta-analysis presented here, because we were only inter-
ested in the effect of chemotherapy in the curative setting.
Furthermore, we used a more detailed distinction of the
employed radiation fractionation schedules in combina-
tion with chemotherapy compared to the MACH-NC
meta-analysis. The advantage of the MACH-NC meta-
analysis is, however, that individual patient's data were
used rather than available data from published materials
as were mainly the basis for the meta-analysis presented
here. One may argue against the "picking" of studies
according to quite strict inclusion criteria. Our inclusion
criteria are justified by the concentration on chemother-
apy schedules still in use. The unusual end point (median
survival time) was chosen because the model fit with the
lognormal distribution showed that the conventional
hazard ratios are not meaningful because they decline
with time. The usual analysis methods based on the
logrank test and the Cox proportional hazard model are
therefore not appropriate, because they assume constant
hazard ratios.
Regardless of these considerations, it is evident that simul-
taneous chemoradiation in locally advanced head and
neck cancer results in a large survival benefit, if modern
chemotherapy regimens are administered simultaneously
with conventionally fractionated or hyperfractionated –
accelerated radiotherapy, and that this benefit is probably
underestimated by the update of the MACH-NC meta-
analysis. The less pronounced survival advantage
observed in studies with prolonged overall treatment
times (average ~17 days) for combined treatments indi-
cate that tumour cell repopulation is still a problem, when
chemoradiation is used. Assuming a repopulation rate
accounting for 0.3 Gy per day [16] and a reported average
steepness of the dose response curves for head and neck
cancer (γ50 ~1.5 according to Okunieff et al. [17]) one
would expect approximately 11% loss in loco-regional
tumour control for a prolongation of the overall treat-
ment time of 17 days. This can roughly be expected to
translate into a survival advantage of 7%, representing
approximately the magnitude of the decrease that was
estimated in the meta-analysis presented here (Figure 1).
The size of the survival benefit in favour of chemoradia-
tion was almost identical regardless whether mono-chem-
otherapy or poly-chemotherapy was used (data not
shown). Differentiated by cytostatic drugs 5-FU and cispl-
Table 4: Comparison of accelerated or hyperfractionated radiotherapy with conventionally fractionated radiotherapy (Group 2/3)
control arm experimental arm












group 2 conventional fract. acceleration
Dische [16] 20 66 45.5 54 12 CHART 72 6
Dobrowsky [37] 21 70 49.0 55.3 17 CHART 12
Olmi [41] 22 68 47.3 65.6 42.7 AF split 70 7
Fu [42] 23 70 49.0 67.2 43.4 AF split 68 13
v. den Bogaert [43] 24 72.5 56.0 69.6 44.8 AF split 65 47
Horiot [23] 25 70 51.7 72 35 AF split 0 0
Fu [42] 26 70 49.0 72 42 concomittant boost
Overgaard [44] 27 66–68 39.0 66–68 46.0 weekend 25
Skladowsky [13] 28 70.6 54 70.75 40 weekend 17 0
group 3 conventional fract. hyperfractionation
Sanchiz [18] 29 60 42.0 70.4 44.8 HFX 30
Pinto [45] 30 66 46.2 70.4 44.8 HFX 54 25
Horiot [46] 31 70 51.1 80.5 49 HFX 15
Fu [42] 32 70 49.0 81.6 47.6 HFX 68 13BMC Cancer 2006, 6:28 http://www.biomedcentral.com/1471-2407/6/28
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atin appear to be more effective than carboplatin and
mitomycin C. This is in agreement with the observations
of the update of the MACH-NC meta-analysis, but cannot
be regarded as prove for the superiority of the one or the
other chemotherapy regimen. No randomized data are
available for newer cytostatic drugs like taxanes that have
been shown to be effective in head and neck cancer.
Hyperfractionated and acceleration of radiation therapy
Radiobiological research predicted that by using hyper-
fractionated radiotherapy, one should be able to increase
total radiation dose without an enhancement of late tox-
icity, but with a higher effectiveness of radiotherapy
against the tumour. As shown in Figure 6, in terms of effi-
cacy at the tumour, this prediction is unequivocally sup-
ported by the outcome of the clinical trials. An overall
survival benefit has been observed in all four trials sug-
gesting an average survival gain of 14.1 months in the
meta-analysis. Even after exclusion of the trial performed
by Sanchiz et al. [18] that has been criticized for question-
able quality [19], the remaining trials still show a statisti-
cally significant survival benefit. However, it is important
to keep in mind that we included solely trials that used at
least a 5% increase in total dose in the hyperfractionated
arm without a significant change in overall treatment
time. In studies testing hyperfractionation without dose
escalation a consistent survival advantage could not be
demonstrated [3,20], that is, hyperfractionation per se
does not result in a survival benefit, but dose escalation
combined with hyperfractionation does. Hyperfractiona-
tion is simply the tool to enable dose escalation without
an increase of severe late toxicity. The toxicities reported
from the randomized trials suggest that hyperfractiona-
tion with dose escalation increases acute mucosal toxicity,
but does not seem to induce significantly more severe late
effects compared with conventional fractionation. How-
ever, late toxicity was not systematically assessed and
reported in all studies so that a moderate increase of late
toxicity cannot be excluded. The large survival benefit
shown for hyperfractionation in combination with dose
escalation clearly prevails the uncertainties regarding the
toxicity.
Another prediction from radiobiological research [21]
and retrospective clinical data [22] was that one should
get better results by decreasing the overall treatment time
of radiation therapy. The results of the CHART head and
neck trial that compared 66 Gy in 46 days to 54 Gy in 12
days, proved that tumour cell repopulation during radia-
tion therapy is an important clinical problem, although
no gain in loco-regional tumour control or overall sur-
vival could be demonstrated for the accelerated radiation
schedule in this study [16]. The concept of acceleration
has been tested in a considerable number of randomised
clinical trials (Table 4). Although many radiation oncolo-
gists regard accelerated treatment as beneficial for head
and neck cancer patients, in the meta-analysis presented
here, we were unable to demonstrate any significant sur-
vival benefit for accelerated radiation therapy (Figure 5).
Eight out of nine studies were negative and the only trial
showing a significant survival advantage is the smallest of
all trials. This discrepancy deserves a closer look to the
studies. Acceleration of radiotherapy was realized in three
different ways: 1) by decreasing the overall treatment by
more than 60% requiring a decrease in total dose of
approximately 20% [16,37], 2) by a moderate reduction
of the overall treatment time without a relevant compro-
mise in total dose using split course radiotherapy regi-
mens [23,41-43], and 3) by a moderate reduction of the
overall treatment time without a relevant compromise in
total dose using 6 or 7 fractions per week [13,44] or a con-
comitant boost radiotherapy regimen [42] without split.
Comparison of hyperfractionated radiotherapy with conventionally fractionated radiotherapy (Group 3) Figure 6
Comparison of hyperfractionated radiotherapy with conventionally fractionated radiotherapy (Group 3). OS = Overall survival; 
* = 95% confidence limits of 2 year overall survival; delta months = differences of median overall survival; LCL = lower confi-
dence limit of median survival; UCL = upper confidence limit of median survival; N = number of patients.BMC Cancer 2006, 6:28 http://www.biomedcentral.com/1471-2407/6/28
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The first strategy trades dose for time and results neither in
a gain of local tumour control nor of overall survival.
Using the second strategy (split course), a significant
improvement of loco-regional tumour control was
observed in one [23] out of four studies. However, the bet-
ter loco-regional tumour control in the EORTC 22851
trial [23] did not translate into an improved overall sur-
vival, which is likely to be a consequence of the signifi-
cantly higher rate of severe late toxicities in the accelerated
arm of the study resulting in an increase in the non cancer
related death rate. The third strategy seems to work better.
All three studies reported a significantly improved local
tumour control [13,42,44] and one study, albeit the
smallest, found a significant survival benefit [13]. The lack
of a survival benefit in the DAHANCA trial [44] might be
explained by the observation that in contrast to local
tumour control, regional tumour control was not
improved by acceleration and that routine neck dissection
for persistent neck disease was not done in this study. The
third trial used a concomitant boost radiation regimen
[42] and observed a non significant improvement of over-
all survival.
Taken together, it appears that accelerated treatments
using split course radiation schedules or reduced total
doses results in no gain of loco-regional tumour control
or overall survival. Accelerated treatments employing con-
tinuous radiation schedules without compromise in total
dose improve local tumour control. The improvement of
local tumour control in this subgroup of studies trans-
lated into a small, but non-significant survival benefit in
the current meta-analysis. More data on this subgroup are
needed.
Conclusion
Radiation therapy combined with simultaneous 5-FU, cis-
platin, carboplatin, and mitomycin C as single drug or
combinations of 5-FU with one of the other drugs results
in a large survival advantage irrespective the employed
radiation schedule. If radiation therapy is used as single
modality, hyperfractionation leads to a significant
improvement of overall survival. Accelerated radiation
therapy alone, especially when given as split course radia-
tion schedule or extremely accelerated treatments with
decreased total dose, does not increase overall survival.
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